Good question. My guess is no—i.e. that ENTA will try to demonstrate that 5 days of EDP-235 is sufficient to get the job done and that this may be a point of differentiation compared to Paxlovid.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.